Advances in Immunosuppressive Agents Based on Signal Pathway.

Area of Science:

• Immunopharmacology
• Molecular Biology
• Drug Development

Background:

• Immune abnormalities underlie diverse diseases including infections, allergies, autoimmune disorders, and transplant rejection.
• Key signaling pathways (JAK/STAT, NF-κB, PI3K/AKT-mTOR, MAPK, Keap1/Nrf2/ARE) are crucial for immune response regulation.
• Targeting these pathways has led to the development of novel immunosuppressive agents.

Purpose of the Study:

• To classify existing and emerging immunosuppressive agents based on their immunopharmacological mechanisms.
• To provide a comprehensive summary of the developmental stages (preclinical, clinical trials, approved) of these agents.
• To highlight the therapeutic potential of targeting specific immune signaling pathways.

Main Methods:

• Literature review and synthesis of existing research on immunosuppressive agents.
• Classification of agents based on targeted molecular pathways and mechanisms of action.
• Categorization of agents according to their clinical development phase.

Main Results:

• Identified and categorized multiple immunosuppressive agents targeting key immune signaling pathways.
• Summarized the clinical status of various immunosuppressive drugs, including approved therapies (e.g., tofacitinib, everolimus) and those in development.
• Demonstrated the therapeutic efficacy of targeted immunosuppression in managing immune-related conditions.

Conclusions:

• Immunosuppressive agents targeting distinct signaling pathways offer effective therapeutic strategies for immune-related diseases.
• The ongoing development of these agents, from preclinical to clinical stages, promises expanded treatment options.
• Understanding immunopharmacological mechanisms is vital for advancing immunosuppressive drug discovery and application.